• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma

byTeddy Guo
April 28, 2023
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

 

Click to read this study in The Lancet Oncology. 

RELATED REPORTS

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma

Ipilimumab/Nivolumab versus Nivolumab in Melanoma Brain Metastases

Tags: advanced melanomaAtezolizumabBRAF-mutated melanomacobimetinibcutaneous melanomafulminant hepatitishepatic failureliver failuremelanomaskin cancerVemurafenib
Previous Post

Neuropsychological and biomechanical measures dominate assessment of limb pain in athletes

Next Post

#VisualAbstract: Intrapartum azithromycin does not reduce neonatal sepsis or mortality

RelatedReports

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
AI Roundup

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

June 12, 2025
Significant reduction in prostate screening rates after revised guidelines
Chronic Disease

BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma

April 28, 2025
“No Evidence of Disease Activity” may be useful goal in multiple sclerosis
Chronic Disease

Ipilimumab/Nivolumab versus Nivolumab in Melanoma Brain Metastases

February 24, 2025
Increased risk of subsequent melanoma after first melanoma diagnosis
Dermatology

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

December 12, 2024
Next Post
#VisualAbstract: Intrapartum azithromycin does not reduce neonatal sepsis or mortality

#VisualAbstract: Intrapartum azithromycin does not reduce neonatal sepsis or mortality

Study explores effects of daily iron supplementation in 2- to 5-year-olds

Etranacogene dezaparvovec gene therapy reduces bleeding in severe hemophilia B

Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact

Sodium bicarbonate does not prevent declining kidney function in kidney transplant recipients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transcatheter closure of patent ductus arteriosus demonstrates similar outcomes compared to surgical repair
  • #VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer
  • Use of psychiatric medications may be associated with a higher risk of amyotrophic lateral sclerosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.